the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-five (1:5).

the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-eighty-five (1:85).

100.00%

Organization and Basis of Presentation (Details)	Mar. 25, 2026	Jun. 13, 2025	Dec. 15, 2023
Common Stock [Member]
Organization and Basis of Presentation [Line Items]
Reverse stock split ratio description	the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-five (1:5).	the Company effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-eighty-five (1:85).
Onconetix, Inc. [Member]
Organization and Basis of Presentation [Line Items]
Subsidiary owned, percentage			100.00%
Proteomedix [Member]
Organization and Basis of Presentation [Line Items]
Subsidiary owned, percentage			100.00%